E
Aequus Pharmaceuticals Inc.
AQS.V
TSX
E
Sell
10/12/2023Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 10/12/2023 due to a decline in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 10/12/2023 due to a decline in the total return index and volatility index.
D
Sell
9/27/2023Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 9/27/2023 due to an increase in the volatility index and valuation index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 9/27/2023 due to an increase in the volatility index and valuation index.
E
Sell
9/8/2023Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 9/8/2023 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 0.02 to 0.01, and debt to equity increased from -1.04 to -0.95.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 9/8/2023 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 0.02 to 0.01, and debt to equity increased from -1.04 to -0.95.
D
Sell
8/29/2023Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 8/29/2023 due to an increase in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 8/29/2023 due to an increase in the volatility index and total return index.
E
Sell
8/14/2023Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 8/14/2023 due to a decline in the volatility index and growth index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 8/14/2023 due to a decline in the volatility index and growth index.
D
Sell
7/28/2023Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 7/28/2023 due to an increase in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 7/28/2023 due to an increase in the total return index and volatility index.
E
Sell
6/7/2023Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 6/7/2023 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.25 to 0.02, and debt to equity increased from -1.51 to -1.04.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 6/7/2023 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.25 to 0.02, and debt to equity increased from -1.51 to -1.04.
D
Sell
6/2/2023Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 6/2/2023 due to an increase in the total return index, volatility index and valuation index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 6/2/2023 due to an increase in the total return index, volatility index and valuation index.
E
Sell
3/14/2023Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
3/1/2023Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 3/1/2023 due to an increase in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 3/1/2023 due to an increase in the volatility index and total return index.
D
Sell
2/23/2023Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
1/17/2023Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 1/17/2023 due to a decline in the total return index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 1/17/2023 due to a decline in the total return index.
D
Sell
12/30/2022Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 12/30/2022 due to an increase in the total return index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 12/30/2022 due to an increase in the total return index.
D
Sell
12/15/2022Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 12/15/2022 due to a decline in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 12/15/2022 due to a decline in the total return index and volatility index.
D
Sell
11/30/2022Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 11/30/2022 due to an increase in the valuation index and volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 11/30/2022 due to an increase in the valuation index and volatility index.
D
Sell
10/21/2022Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 10/21/2022 due to a decline in the volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 10/21/2022 due to a decline in the volatility index.
D
Sell
10/6/2022Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 10/6/2022 due to an increase in the volatility index and valuation index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 10/6/2022 due to an increase in the volatility index and valuation index.
D
Sell
9/19/2022Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 9/19/2022 due to a decline in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 9/19/2022 due to a decline in the total return index and volatility index.
D
Sell
8/30/2022Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 8/30/2022 due to a large increase in the growth index and volatility index. Earnings per share increased from -$0.0055 to -$0.0046, total revenue increased 13.78% from $238.7 to $271.6, and EBIT increased 12.49% from -$684 to -$598.6.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 8/30/2022 due to a large increase in the growth index and volatility index. Earnings per share increased from -$0.0055 to -$0.0046, total revenue increased 13.78% from $238.7 to $271.6, and EBIT increased 12.49% from -$684 to -$598.6.
D
Sell
7/1/2022Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 7/1/2022 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.0019 to -$0.0055, debt to equity increased from 1.18 to 2.39, and total revenue declined 65% from $682 to $238.7.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 7/1/2022 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.0019 to -$0.0055, debt to equity increased from 1.18 to 2.39, and total revenue declined 65% from $682 to $238.7.
D
Sell
5/16/2022Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.
E
Sell
5/13/2022Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D on 05/13/2022.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D on 05/13/2022.
D
Sell
5/4/2022Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from E+ on 05/04/2022.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
E
Sell
4/20/2022Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index and volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
11/9/2021Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from E+ on 11/09/2021.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
5/1/2020Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 05/01/2020.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 05/01/2020.
D
Sell
4/30/2020Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 4/30/2020 due to a noticeable increase in the valuation index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 4/30/2020 due to a noticeable increase in the valuation index.
E
Sell
4/13/2020Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 4/13/2020 due to a decline in the volatility index, total return index and valuation index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 4/13/2020 due to a decline in the volatility index, total return index and valuation index.
D
Sell
3/27/2020Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 3/27/2020 due to an increase in the total return index, growth index and volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 3/27/2020 due to an increase in the total return index, growth index and volatility index.
E
Sell
1/21/2020Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 1/21/2020 due to a decline in the volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 1/21/2020 due to a decline in the volatility index.
D
Sell
1/2/2020Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 1/2/2020 due to an increase in the valuation index and volatility index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 1/2/2020 due to an increase in the valuation index and volatility index.
E
Sell
11/29/2019Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 11/29/2019 due to a significant decline in the solvency index, total return index and growth index. Debt to equity increased from 2 to 9.2, the quick ratio declined from 4.25 to 2.66, and total revenue declined 5.45% from $297 to $280.8.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 11/29/2019 due to a significant decline in the solvency index, total return index and growth index. Debt to equity increased from 2 to 9.2, the quick ratio declined from 4.25 to 2.66, and total revenue declined 5.45% from $297 to $280.8.
D
Sell
11/30/2018Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 11/30/2018 due to an increase in the total return index, efficiency index and valuation index. Total capital increased 76.58% from $983.2 to $1.74M, and net income increased 3.43% from -$516.3 to -$498.6.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 11/30/2018 due to an increase in the total return index, efficiency index and valuation index. Total capital increased 76.58% from $983.2 to $1.74M, and net income increased 3.43% from -$516.3 to -$498.6.
E
Sell
8/28/2018Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 8/28/2018 due to a noticeable decline in the total return index, volatility index and efficiency index. Total capital declined 31.64% from $1.44M to $983.2.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 8/28/2018 due to a noticeable decline in the total return index, volatility index and efficiency index. Total capital declined 31.64% from $1.44M to $983.2.
D
Sell
6/5/2018Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 6/5/2018 due to an increase in the solvency index and efficiency index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 6/5/2018 due to an increase in the solvency index and efficiency index.
E
Sell
5/30/2018Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 5/30/2018 due to a decline in the efficiency index and solvency index. Total capital declined 17.84% from $2.24M to $1.84M.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 5/30/2018 due to a decline in the efficiency index and solvency index. Total capital declined 17.84% from $2.24M to $1.84M.
D
Sell
2/13/2018Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 2/13/2018 due to a noticeable increase in the growth index, volatility index and total return index. Total revenue increased 67.36% from $138.8 to $232.3, EBIT increased 24.78% from -$1.03M to -$771.1, and earnings per share increased from -$0.0133 to -$0.0106.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 2/13/2018 due to a noticeable increase in the growth index, volatility index and total return index. Total revenue increased 67.36% from $138.8 to $232.3, EBIT increased 24.78% from -$1.03M to -$771.1, and earnings per share increased from -$0.0133 to -$0.0106.
E
Sell
8/31/2017Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 8/31/2017 due to a decline in the efficiency index, volatility index and growth index. Total revenue declined 37.28% from $221.3 to $138.8, EBIT declined 33.83% from -$766 to -$1.03M, and net income declined 24.09% from -$765.5 to -$949.9.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 8/31/2017 due to a decline in the efficiency index, volatility index and growth index. Total revenue declined 37.28% from $221.3 to $138.8, EBIT declined 33.83% from -$766 to -$1.03M, and net income declined 24.09% from -$765.5 to -$949.9.
D
Sell
5/2/2017Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 5/2/2017 due to a significant decline in the growth index, solvency index and efficiency index. The quick ratio declined from 2.24 to 0.89, total capital declined 45.82% from $1.74M to $942.3, and total revenue declined 45.61% from $230 to $125.1.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to D- from D on 5/2/2017 due to a significant decline in the growth index, solvency index and efficiency index. The quick ratio declined from 2.24 to 0.89, total capital declined 45.82% from $1.74M to $942.3, and total revenue declined 45.61% from $230 to $125.1.
D
Sell
12/1/2016Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 12/1/2016 due to a significant increase in the growth index, efficiency index and valuation index. Total capital increased 180.09% from $620.9 to $1.74M, total revenue increased 151.15% from $91.7 to $230.3, and earnings per share increased from -$0.024 to -$0.0179.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D from D- on 12/1/2016 due to a significant increase in the growth index, efficiency index and valuation index. Total capital increased 180.09% from $620.9 to $1.74M, total revenue increased 151.15% from $91.7 to $230.3, and earnings per share increased from -$0.024 to -$0.0179.
D
Sell
8/31/2016Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 8/31/2016 due to a noticeable increase in the growth index and solvency index. Operating cash flow increased 72.71% from -$1.25M to -$341, and total revenue increased 8.26% from $84.7 to $91.7.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E+ on 8/31/2016 due to a noticeable increase in the growth index and solvency index. Operating cash flow increased 72.71% from -$1.25M to -$341, and total revenue increased 8.26% from $84.7 to $91.7.
E
Sell
5/2/2016Downgrade
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 5/2/2016 due to a noticeable decline in the volatility index, growth index and total return index. Operating cash flow declined 24.23% from -$529.5 to -$657.8, and EBIT declined 13.59% from -$1.04M to -$1.18M.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E+ from D- on 5/2/2016 due to a noticeable decline in the volatility index, growth index and total return index. Operating cash flow declined 24.23% from -$529.5 to -$657.8, and EBIT declined 13.59% from -$1.04M to -$1.18M.
D
Sell
12/1/2015Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E on 12/1/2015 due to an increase in the growth index and volatility index. EBIT increased 27.09% from -$816.9 to -$1.04M, and earnings per share increased from -$0.0244 to -$0.0289.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to D- from E on 12/1/2015 due to an increase in the growth index and volatility index. EBIT increased 27.09% from -$816.9 to -$1.04M, and earnings per share increased from -$0.0244 to -$0.0289.
E
Sell
9/1/2015Upgraded
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to E from E- on 9/1/2015 due to an increase in the total return index and valuation index.
Aequus Pharmaceuticals Inc. (AQS.V) was upgraded to E from E- on 9/1/2015 due to an increase in the total return index and valuation index.
E
Sell
6/10/2015None
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E- from U on 06/10/2015.
Aequus Pharmaceuticals Inc. (AQS.V) was downgraded to E- from U on 06/10/2015.
